

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

FOREST LABORATORIES, INC., FOREST )  
LABORATORIES HOLDINGS, LTD. & )  
ROYALTY PHARMA COLLECTION )  
TRUST, )

Plaintiffs, )

v. )

SANDOZ INC., )

Defendant. )

C.A. No. \_\_\_\_\_

**COMPLAINT FOR PATENT INFRINGEMENT**

1. Plaintiffs Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd., and Royalty Pharma Collection Trust (collectively, "Plaintiffs") file this Complaint for patent infringement against Sandoz Inc. ("Sandoz") under 35 U.S.C. §§ 271(e)(2), (b) and (c). This patent action concerns the pharmaceutical drug product Savella<sup>®</sup>. Plaintiffs hereby state as follows:

**JURISDICTION AND PARTIES**

2. Plaintiff Forest Laboratories, Inc. ("Forest Labs.") is a Delaware corporation having a principal place of business at 909 Third Avenue, New York, New York, 10022.

3. Plaintiff Forest Laboratories Holdings, Ltd. is an Irish corporation having a principal place of business at Columbia House, 1 Victoria Street, Hamilton HM11, Bermuda (referred to herein, together with Forest Labs. as "Forest").

4. Plaintiff Royalty Pharma Collection Trust ("Royalty Pharma") is a Delaware trust having a principal place of business at Rodney Square North, 1100 North Market Street, Wilmington, Delaware 19890-0001.

5. On information and belief, Sandoz is a corporation organized under the laws of Colorado, having a principal place of business at 506 Carnegie Center, Suite 400, Princeton, New Jersey 08540.

6. On information and belief, Sandoz is a pharmaceutical company that is registered to distribute drugs in the State of Delaware and formulates, manufactures, packages and markets generic drug products for distribution in the District of Delaware and throughout the United States.

7. On information and belief, Sandoz derives substantial revenue from the sale of its products in Delaware and throughout the United States.

8. On information and belief, Sandoz is amenable to litigating in this forum based on Sandoz's conduct in numerous other litigations in this District. In particular, Sandoz has elected not to contest personal jurisdiction on several different occasions as a defendant in this District, and has previously availed itself of this Court by filing suit and asserting counterclaims in other civil actions initiated in this jurisdiction.

9. This Court has personal jurisdiction over Sandoz by virtue of, among other things: (1) its registration to distribute drugs in Delaware; (2) its sale and distribution of generic drugs in Delaware; (3) its course of conduct that is designed to cause the performance of the tortious act of patent infringement that has led to foreseeable harm and injury to Plaintiffs, including Plaintiffs Forest Labs. and Royalty Pharma, which are Delaware corporations; (4) its purposeful availment of this forum previously for the purpose of litigating a patent dispute; and (5) its admission that it is subject to the Court's jurisdiction in other patent litigations.

10. This patent infringement action arises under the United States Patent Laws, Title 35 U.S.C. § 100 *et seq.* This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331,

1338(a), 2201, and 2202. Venue is proper in this judicial district under 28 U.S.C. §§ 1391 and 1400(b).

### **COUNT I FOR PATENT INFRINGEMENT**

11. Plaintiffs reallege and incorporate by reference paragraphs 1-10.

12. United States Patent No. 6,602,911 (“the ’911 patent”), titled “Methods of Treating Fibromyalgia,” was duly and legally issued to inventors Jay D. Kranzler and Srinivas G. Rao by the United States Patent and Trademark Office (“PTO”) on August 5, 2003. The ’911 patent is currently assigned to Royalty Pharma and expires on January 14, 2023. This expiration date includes a 435 day patent term extension granted by the PTO pursuant to 35 U.S.C. § 156(b). A true and correct copy of the ’911 patent is attached as Exhibit A. A true and correct copy of the Certificate Extending Patent Term is attached as Exhibit B.

13. United States Patent No. 7,888,342 (“the ’342 patent”), titled “Methods of Treating Fibromyalgia Syndrome, Chronic Fatigue Syndrome and Pain,” was duly and legally issued to inventors Jay D. Kranzler and Srinivas G. Rao by the PTO on February 15, 2011. The ’342 patent is currently assigned to Royalty Pharma and expires on November 5, 2021. A true and correct copy of the ’342 patent is attached as Exhibit C.

14. United States Patent No. 7,994,220 (“the ’220 patent”), titled “Milnacipran for the Long-Term Treatment of Fibromyalgia Syndrome,” was duly and legally issued to inventors Srinivas G. Rao, Michael Gendreau, and Jay D. Kranzler by the PTO on August 9, 2011. The ’220 patent is currently assigned to Royalty Pharma and expires on September 19, 2029. This expiration date includes a 1089 day patent term adjustment granted by the PTO pursuant to 35 U.S.C. § 154(b). A true and correct copy of the ’220 patent is attached as Exhibit D. A true and

correct copy of the Issue Notification reflecting the patent term adjustment is attached as Exhibit E.

15. New Drug Application (“NDA”) No. 022256 is directed to the use of Savella<sup>®</sup> in the management of fibromyalgia. The FDA approved NDA No. 022256 on January 14, 2009. The ’911, ’342, and ’220 patents are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (“the Orange Book”) for NDA No. 022256.

16. Plaintiff Forest is the exclusive licensee of the ’911, ’342, and ’220 patents. Plaintiff Forest is the exclusive distributor of tablets containing 12.5 mg, 25 mg, 50 mg, and 100 mg of the active ingredient milnacipran hydrochloride in the United States, which are sold under the brand name Savella<sup>®</sup>.

17. On information and belief, Sandoz filed ANDA No. 205225 with the FDA under 21 U.S.C. § 355(j), seeking to obtain approval for the commercial manufacture, use, and sale of milnacipran hydrochloride tablets in 12.5 mg, 25 mg, 50 mg, and 100 mg dosage strengths (“Sandoz’s generic milnacipran product”) in the United States before the expiration of the ’911, ’342, and ’220 patents.

18. On information and belief, ANDA No. 205225 contains a Paragraph IV certification alleging that the claims of the ’911, ’342, and ’220 patents are invalid and/or not infringed.

19. Sandoz sent to Plaintiffs a letter dated October 22, 2013 (“the Notice Letter”) notifying Plaintiffs that Sandoz had submitted ANDA No. 205225, and providing information pursuant to 21 U.S.C. § 355(j)(2)(B)(ii). The Notice Letter alleges invalidity of claims 1-3 and 5-7 of the ’911 patent, claims 1-10 of the ’342 patent and claims 1-7 of the ’220 patent. The

notice letter did not allege noninfringement of any claims of the '342, or '220 patents and did not allege noninfringement of claims 1-3 and 5-7 of the '911 patent.

20. On information and belief, Sandoz seeks approval of at least one indication for Sandoz's generic milnacipran product that is claimed in the '911, '342, and '220 patents.

21. Under 35 U.S.C. § 271(e)(2)(A), Sandoz infringed one or more claims of the '911, '342, and '220 patents, in violation of Plaintiffs' patent rights, by submitting to the FDA an ANDA that seeks approval to commercially market—before the expiration date of the '911, '342, and '220 patents—Sandoz's generic milnacipran product, the use of which would directly infringe one or more claims of the '911, '342, and '220 patents, and the manufacture and sale of which would contribute to or induce the direct infringement of one or more claims of the '911, '342, and '220 patents by users of Sandoz's generic milnacipran product.

22. On information and belief, Sandoz has knowledge of the '911, '342, and '220 patents and has filed ANDA No. 205225 seeking authorization to commercially manufacture, use, offer for sale, and sell Sandoz's generic milnacipran product in the United States. On information and belief, if the FDA approves ANDA No. 205225, physicians, health care providers, and/or patients will use Sandoz's generic milnacipran product in accordance with the instructions and/or label provided by Sandoz and will directly infringe one or more claims of the '911, '342, and '220 patents.

23. On information and belief, Sandoz knows and intends that physicians, health care providers, and/or patients will use Sandoz's generic milnacipran product in accordance with the instructions and/or label provided by Sandoz, and will therefore induce infringement of one or more of the claims of the '911, '342, and '220 patents with the requisite intent.

24. On information and belief, if the FDA approves ANDA No. 205225, Sandoz will sell or offer to sell its generic milnacipran product specifically labeled for use in practicing one or more of the method claims of the '911, '342, and '220 patents, wherein Sandoz's generic milnacipran product is a material part of the method claimed, wherein Sandoz knows that physicians will prescribe and patients will use Sandoz's generic milnacipran product in practicing one or more of the methods claimed in the '911, '342, and '220 patents, and wherein milnacipran is not a staple article or commodity of commerce suitable for substantial noninfringing use. Sandoz will thus contribute to the infringement of the '911, '342, and '220 patents.

25. Plaintiffs will be substantially and irreparably harmed by Sandoz's infringing activities unless those activities are enjoined by this Court. Plaintiffs have no adequate remedy at law.

## **COUNT II FOR DECLARATORY JUDGMENT**

26. Plaintiffs reallege and incorporate by reference paragraphs 1-25.

27. This declaratory judgment claim arises under the United States Patent Laws, 35 U.S.C. § 100 et seq., including 35 U.S.C. § 271(b)-(c), and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

28. The manufacture, sale, offer for sale, and/or importation of Sandoz's generic milnacipran product so labeled, if approved by the FDA, will induce and contribute to the infringement of one or more claims of the '911, '342, and '220 patents under 35 U.S.C. § 271(b) and/or (c), in violation of Plaintiffs' patent rights.

29. On information and belief, Sandoz has knowledge of the '911, '342, and '220 patents and has filed ANDA No. 205225 seeking authorization to commercially manufacture,

use, offer for sale, and sell Sandoz's generic milnacipran product in the United States. On information and belief, if the FDA approves ANDA No. 205225, physicians, health care providers, and/or patients will use Sandoz's generic milnacipran product in accordance with the instructions and/or label provided by Sandoz and will directly infringe one or more claims of the '911, '342, and '220 patents.

30. On information and belief, Sandoz knows and intends that physicians, health care providers, and/or patients will use Sandoz's generic milnacipran product in accordance with the instructions and/or label provided by Sandoz, and will therefore induce infringement of one or more of the claims of the '911, '342, and '220 patents with the requisite intent under 35 U.S.C. § 271(b).

31. On information and belief, if the FDA approves ANDA No. 205225, Sandoz will sell or offer to sell its generic milnacipran product specifically labeled for use in practicing one or more of the method claims of the '911, '342, and '220 patents, wherein Sandoz's generic milnacipran product is a material part of the method claimed in the '911, '342, and '220 patents, wherein Sandoz knows that physicians will prescribe and patients will use Sandoz's generic milnacipran product for one or more of the methods claimed in the '911, '342, and '220 patents, and wherein milnacipran is not a staple article or commodity of commerce suitable for substantial noninfringing use. Sandoz will thus contribute to the infringement of the '911, '342, and '220 patents under 35 U.S.C. § 271(c).

32. As a result of the foregoing facts, there is a real, substantial, and continuing justiciable controversy between Plaintiffs and Sandoz as to liability for the infringement of the '911, '342, and '220 patents claims. Sandoz's actions have created in Plaintiffs a reasonable apprehension of irreparable harm and loss resulting from Sandoz's threatened imminent actions.

### **PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in its favor as follows:

(a) declare that United States Patent Nos. 6,602,911, 7,888,342, and 7,994,220 are valid;

(b) declare that, under 35 U.S.C. § 271(e)(2)(A), Sandoz infringed United States Patent Nos. 6,602,911, 7,888,342, and 7,994,220 by submitting ANDA No. 205225 to the FDA to obtain approval to commercially manufacture, use, offer for sale, sell, or import into the United States Sandoz's generic milnacipran product prior to the expiration of said patents;

(c) declare that Sandoz's commercial manufacture, use or sale, or offer for sale in, or importation into the United States of Sandoz's generic milnacipran product prior to the expiration of United States Patent Nos. 6,602,911, 7,888,342, and 7,994,220 would constitute infringement of one or more claims of said patents under 35 U.S.C. § 271 (b) and/or (c);

(d) order that the effective date of any FDA approval of Sandoz's generic milnacipran product shall be no earlier than the expiration date of United States Patent Nos. 6,602,911, 7,888,342, and 7,994,220, including any exclusivities or extensions to which Plaintiffs are or become entitled, in accordance with 35 U.S.C. § 271(e)(4)(A);

(e) enjoin Sandoz, and all persons acting in concert with Sandoz, from seeking, obtaining, or maintaining final approval of ANDA No. 205225 until the expiration of United States Patent Nos. 6,602,911, 7,888,342, and 7,994,220, including any exclusivities or extensions to which Plaintiffs are or become entitled;

(f) enjoin Sandoz and all persons acting in concert with Sandoz, from commercially manufacturing, using, offering for sale, or selling Sandoz's generic milnacipran



product within the United States, or importing Sandoz's generic milnacipran product into the United States, until the expiration of United States Patent Nos. 6,602,911, 7,888,342, and 7,994,220, including any exclusivities or extensions to which Plaintiffs are or become entitled, in accordance with 35 U.S.C. § 271(e)(4)(B);

(g) declare this to be an exceptional case and award Plaintiffs their costs, expenses, and disbursements in this action, including reasonable attorney fees, pursuant to 35 U.S.C. §§ 285 and 271(e)(4); and

(h) grant Plaintiffs such further and additional relief that this Court deems just and proper.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP



Jack B. Blumenfeld (#1014)  
Maryellen Noreika (#3208)  
1201 North Market Street  
P.O. Box 1347  
Wilmington, DE 19899  
(302) 658-9200  
[jblumenfeld@mnat.com](mailto:jblumenfeld@mnat.com)  
[mnoreika@mnat.com](mailto:mnoreika@mnat.com)

*Attorneys for Plaintiffs*

OF COUNSEL:

Charles E. Lipsey  
FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, LLP  
Two Freedom Square  
11955 Freedom Drive.  
Reston, VA 20190-5675  
(571) 203-2700

Howard W. Levine  
Sanya Sukduang  
Courtney B. Casp  
FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, LLP  
901 New York Avenue, NW  
Washington, DC 20001-4413  
(202) 408-4000

November 4, 2013